Evogene (EVGN) Fundamentals 2026 — Revenue Analysis | SniperIQ
Evogene (EVGN) is a IL-listed Healthcare company in Biotechnology with a market capitalization of $5M, trading at $0.55 on the NASDAQ. This SniperIQ fundamentals page covers Evogene's valuation, profitability (net margin -639.4%), revenue ($4M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Evogene's market cap?
Evogene (EVGN) has a market capitalization of approximately $5M, trading at $0.55 on the NASDAQ. Market cap moves with the live share price.
How profitable is Evogene?
Evogene runs a net profit margin of -639.4%, a gross margin of 30.9%, and an operating margin of -757.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Evogene generate?
Evogene reported revenue of $4M for fiscal year 2025, with net income of -$8M and earnings per share (EPS) of -1.08. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Evogene pay a dividend?
Evogene does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Evogene financially healthy?
Evogene carries a debt-to-equity ratio of -0.80x and a current ratio of 2.77x, with a market beta of 0.78. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Evogene a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Evogene (EVGN) the key facts are: market cap $5M, revenue $4M, 52-week range 0.37-1.5. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Evogene's full fundamentals live
Get Evogene's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.